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Background
Magnesium (Mg2+) has received considerable attention with
regards to its potential role in the pathophysiology of the mood
disorders, but the available evidence seems inconclusive.
Aims
To review and quantitatively summarise the human literature on
Mg2+ intake andMg2+ blood levels in themood disorders and the
effects of Mg2+ supplements on mood.
Method
Systematic review and meta-analyses.
Results
Adherence to a Mg2+-rich diet was negatively associated with
depression in cross-sectional (odds ratio = 0.66) but not in pro-
spective studies. Mg2+ levels in bodily fluids were on average
higher in patients with a mood disorder (Hedge’s g = 0.19), but
only in patients treated with antidepressants and/or mood sta-
bilisers. There was no evident association between Mg2+ levels
and symptom severity. Mg2+ supplementation was associated
with a decline in depressive symptoms in uncontrolled
(g = −1.60) but not in placebo-controlled trials (g = −0.21).
Conclusion
Our results provide little evidence for the involvement of Mg2+
in the mood disorders.
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The trace element magnesium (Mg2+) has an essential role in hun-
dreds of enzymatic reactions.1,2 The Mg2+ in our bodies is derived
from food such as cereals, nuts and (green) vegetables.3–5
Insufficient intake of Mg2+ can cause hypomagnesaemia (i.e. an
Mg2+ level of <0.7 mmol/L).4,6–9 Hypomagnesaemia can also
develop owing to the use of diuretics, defects in absorption or diar-
rhoea.1,5 About 2–15% of the general population has hypomagnes-
aemia. In some populations this percentage is even higher, e.g. it is
14–48% in patients with type 2 diabetes.10Mg2+ deficiencymay pose
a risk to metabolic and cardiovascular health.11,12
Mg2+ and mental health
For over 50 years, the idea has existed that Mg2+ deficiency may also
pose a risk to mental health,13 in particular with respect to (patho-
logical) low mood.14–16 One hypothesis, which attempts to explain
this association, is that Mg2+ deficiency affects brain chemistry,
membrane fluidity and inflammation,1,17,18 all of which are asso-
ciated with psychiatric illnesses19 and the response to antidepres-
sants.17 Furthermore, Mg2+ may protect neurons against cell
death owing to its regulating effects on calcium dynamics.1 Mg2+
is also involved in the glutamatergic system, regulating learning,
memory, neuroplasticity and perhaps antidepressant activity.20
Animal studies
Some preclinical experiments have shown that Mg2+ deficiency is
related to the functioning of limbic brain areas and to behaviour
in rodents that some conceptualise as ‘depression-like’.16,21 The
administration of Mg2+ supplements,22 magnesium sulphate23 and
magnesium chloride24 has been shown to alter this behaviour.
However, owing to a lack of validity of the behavioural read-outs,
the translational value of such experiments is questionable.25,26
Human studies
There is a considerable amount of human data on the topic. Some
studies evaluated whether the prevalence (cross-sectional) or the
incidence (longitudinal) of depression differs as a function of
dietary Mg2 intake.27,28 Others have investigated Mg2+ in bodily
fluids as a function of mood disorder status.29,30 Some experiments
have also investigated whether Mg2+ supplementation can serve as
an antidepressant.31,32
Conflicting findings
However, the findings from these studies appear to be inconclu-
sive,33 and the two meta-analyses on the topic to date do not
provide a high level of evidence either. Cheungpasitporn and collea-
gues34 pooled data from three studies on bloodMg2+ levels with two
studies on dietary Mg2+ intake and concluded from this heteroge-
neous pool of data that hypomagnesaemia is related to depression
(odds ratio (OR) = 1.34). Li and colleagues35 pooled nine cross-sec-
tional and two prospective studies on dietaryMg2+ intake and found
a relative risk of 0.81 for depressive symptoms in people who
adhered to a diet high in Mg2+. However, they did not differentiate
between cross-sectional and longitudinal designs, leaving it open to
interpretation whether dietary Mg2+ intake is a risk factor for
depressive symptoms versus a concomitant phenomenon or a con-
sequence of it.
The conflicting findings in this field may be attributable to mod-
erators, such as the way in which dietary information is acquired or
the blood component in whichMg2+ is measured (e.g. measurement
methods and absolute values of Mg2+ are different for plasma and
serum,36 which may present an additional source of between-
study heterogeneity in outcome). They may also stem from the dif-
fering methodological characteristics of individual studies
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(e.g. sample size, participant characteristics, medication effects) or
from general issues such as publication bias.
The current study
One way to provide a more definitive answer to the question of
whether Mg2+ and mood disorders are related, as well as explaining
the potential causes of heterogeneity in the findings, is to carry out a
systematic review with meta- and moderator analyses covering the
broad literature on this topic. We set out to present such analyses on
the following associations: (a) mood disorder prevalence or inci-
dence by dietary Mg2+ intake, (b) Mg2+ levels in bodily fluids by
mood disorder status and severity, and (c) the effects of Mg2+ sup-
plements on mood.
Method
This project was reported following the guidelines of PRISMA37 and
MOOSE.38 PRISMA and MOOSE checklists can be found in
Appendices 1 and 2, respectively. The review protocol is presented
in appendix 3.
Search strategy
We searched PubMed, Web of Science, and Embase (from their
commencement to 22 December 2017) for eligible papers using
the following terms: (Magnesium OR Mg*) AND (depression OR
depress* OR affect* ORmoodORmania OR bipolar). The reference
lists of identified articles were scrutinised, as were the references that
were made to the two seminal papers on the topic14,15 (to which, at
the date of our latest search, 65 and 5 references were made
respectively).
Study selection
We included human studies that reported original findings on the
following associations: (a) prevalence and/or incidence of depres-
sion as a function of dietary Mg2+ intake, (b) Mg2+ levels in
bodily fluids/blood components as a function of mood disorder
status and/or severity, and (c) changes in mood disorder status as
a function of Mg2+ supplementation. Studies had to be published
in peer-reviewed journals (including advance online publication)
and written in English, French, German, Spanish or Dutch in
order to be included.
In case of overlap among study samples, we excluded the study
that reported on the fewest participants.
Data extraction
From each eligible article, we extracted data on a range of demo-
graphic, clinical and methodological variables, as well as raw
numbers or effect-size estimates (with corresponding 95% confi-
dence intervals) on the associations of interest. Data extraction is
specified in Supplementary Table S1, available at https://doi.org/
10.1192/bjo.2018.22. Authors of articles in which data necessary
to our investigations were missing were contacted by e-mail to
request these data.
Assessment of the eligibility of each publication and data extrac-
tion were performed independently by two of the authors. Cases of
disagreement were resolved by discussion and consensus.
Quality assessment
The methodological quality of cross-sectional and case–control
studies was assessed using the Newcastle–Ottawa scale,39 and that
of prospective studies was assessed using the method proposed by
Lievense et al.40 The methodological quality of treatment trials
was assessed using the method of evaluation of (randomised)
trials provided by the US Department of Health and Human
Services.41
Data analyses
Analyses were performed in STATA version 13.42 Associations were
tested for statistical significance at a two-tailed confidence interval
of 95%. Summary tables on characteristics of eligible papers were
created.
Random-effects meta-analyses were used in all cases to pool the
data. In case of binary outcomes (e.g. incidence of depression), we
calculated the OR as an effect-size estimate. When continuous
data served as the outcome and group membership as the predictor
(e.g. Mg2+ concentrations in patients and healthy control partici-
pants), we calculated Hedge’s g as the measure of effect.
Associations between continuous variables (e.g. Mg2+ concentration
and depression severity) were quantified using Pearson’s r.
Heterogeneity in outcome was quantified using the I2 measure
and its statistical significance was assessed using the χ2 statistic.43
In cases of heterogeneity, moderator analyses were performed.
Predictors of heterogeneity were, where applicable: the medium in
which Mg2+ was determined, type of diagnosis, male/female ratio
and mean age of the sample, type of medication, duration of
follow-up, and the estimated methodological quality of the study.
The sensitivity of our results was further tested by excluding each
single study at a time.
Publication bias was assessed by means of visual inspection of
funnel plots and Egger’s test.43 When evident, trim-and-fill proce-
dures were applied to estimate pooled effect sizes while taking
bias into account.44
Results
We identified 4110 articles after duplicates were removed. Of these,
4053 articles were excluded, leaving 58 that reported on at least one
of the associations of interest. The study selection process, from
initial search to final selection, is presented in Figure 1. Table 1
and Supplementary Table 10 list the articles that were included in
our meta-analyses14,15,27–32,45–94 and provide information on their
characteristics.
Methodological quality of the included studies
In the online Supplementary Tables 2–9, we provide details on the
quality assessment tools that we used. The assessment of study
quality showed a high degree of agreement (∼83% agreement; see
the online supplement formore information) among two independent
assessors (D.P. and M.M.). Item and total quality scores per eligible
study are provided in Supplementary Tables 2–9. Methodological
quality was not used as a criterion for inclusion or exclusion.
The overall methodological quality of the included studies was
modest. In general, most studies applied valid statistical techniques,
although statistical power was seldom reported. Methodological
quality also was hampered by a lack of data on the representativeness
of the sample, and drop-out and response rates.Most studies adjusted
for confounding, ranging from almost absent adjustment to – in our
view – thorough adjustment. Finally, for the treatment studies, no
paper reported on the adequacy of randomisation and allocation
concealment.
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Dietary Mg2+ and the prevalence or incidence of
unipolar depression/depressive symptoms
Adherence to a diet high in Mg2+ was associated with a lower preva-
lence of depression in cross-sectional studies (OR (highest versus
lowest category) = 0.66, 95% CI = 0.51–0.81; P < 0.01, k = 12, n =
21 927), but not in longitudinal cohorts that assessed the incidence
of new-onset depression (OR = 0.71, 95% CI = 0.40–1.02; P = 0.10,
k = 2, n = 18 156).
Between-study heterogeneity in outcome was present in the
cross-sectional studies assessing the association between dietary
Mg2+ intake and depression prevalence, as was as evidence of pub-
lication bias (Figure 2A). Sample size was the only variable (Table 2)
that was associated with between-study heterogeneity; smaller
samples on average yielded stronger associations between dietary
Mg2+ and mood disorder prevalence. The strength of this associ-
ation, in terms of Spearman’s rho (ρ), was 0.61. Correction for the
presence of publication bias led to an attenuated, yet statistically sig-
nificant, effect size estimate (OR = 0.84, 95% CI = 0.70–0.98).
Between-study heterogeneity and publication bias could not be
assessed in the analysis of depression incidence owing to the small
number of studies.
There were no studies which reported on the effects of dietary
Mg2+ on symptoms of bipolar disorder.
Mg2+ levels in bodily fluids as a function of mood
disorder status
Sixty-two effect-size estimates were found for Mg2+ levels in bodily
fluids by mood disorder status. Pooling these data showed higher
Mg2+ levels in patients with a mood disorder, relative to healthy
controls (g = 0.19, 95% CI = 0.05–0.36; P < 0.001, k = 62, n = 4433).
There was between-study heterogeneity (Figure 2B). A large
part of this was due to treatment status, as Mg2+ levels in bodily
fluids were particularly high in patients who were treated with anti-
depressants and/or mood stabilisers (P < 0.01 for the difference
between treated and untreated samples). In fact, Mg2+ levels of
untreated patients were no different from those of controls.
Diagnostic status was also associated with heterogeneity, as the dif-
ferences between patients and controls were larger for samples com-
posed of bipolar depressed patients (Figure 2B) relative to patients
with depressive symptoms/major depression. No evident hetero-
geneity resulted from the medium in which Mg2+ levels were deter-
mined (e.g. plasma versus serum).
A significant association between sample size and effect-size
estimate was observed, indicating that smaller samples on average
yielded larger differences in Mg2+ concentrations between patients
and controls (ρ =−0.42; Table 2). Egger’s t-tests and funnel plots
suggested the presence of publication bias. Correcting for this led
to non-significant between-group differences overall.
Mg2+ levels and symptom severity
Pooling 11 effect-size estimates that reported on continuous asso-
ciations between Mg2+ levels and scores on mood disorder severity
scales showed no evident association between these variables. In
some instances, heterogeneity in outcomes was observed.
However, this remained unexplained in subgroup and sensitivity
analyses (Figure 2C).
Changes in mood disorder status following treatment
with Mg2+ supplements
Eleven studies showed that Mg2+ supplementation was associated
with a decline in symptoms (g =−0.44, 95% CI =−0.68 to −0.20;
Screening: 4110 articles screened
after duplications were removed 
Eligibility: 189 full-text articles
assessed for eligibility  
Excluded: 132 (78 were reviews, meta-
analyses or case-studies; 25 were not on
mood disorders; 21 were not on Mg2; and
7 did not report sufficient data)
Included: 58 independent studies (N = 45 062) included for quantitative synthesis:
I 14 effect sizes on differences in the prevalence and the incidence of depression as a
function of dietary Mg2 intake.
IIa 62 effect sizes on between-group differences in Mg2+ concentrations in bodily fluids/
blood components as a function of mood disorder status.
IIb 11 effect sizes on continuous differences in Mg2+ concentrations in bodily fluids and
blood components as a function of mood disorder severity.
III 11 effect sizes on changes in mood disorder status as a function of treatment with
Mg2+ supplements. 
Note. The number of studies (58) was not the same as the number of effect sizes, owing to the
fact that some studies provided > 1 effect size. 
Identification: 4347 articles were identified in the digital databases Embase, PUBMED and
Web of Science. 23 additional articles were identified through backward searches and by
scrutinizing reference lists of identified articles
Excluded: 3921
Fig. 1 Flowchart on identification, screening and inclusion of eligible articles.
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P < 0.01, k = 11, n = 714). This effect was restricted to uncontrolled
studies (g =−1.62, 95% CI =−2.81 to −0.40) and was not observed
in placebo-controlled studies (g =−0.22, 95% CI =−0.48–0.17;
Figure 2D). The difference between effect-size estimates for con-
trolled versus uncontrolled studies was significant. The remaining
heterogeneity could not be explained by the specified moderators
or publication bias (Figure 2D; Table 2).
Dosage of Mg2+ supplementation (range 225–4000 mg) and
number of weeks of treatment (range 1–12) were unrelated to
outcome.
Table 1 Characteristics of the included studies. Studies are presented by year of publication and in alphabetical order
Author, year Analysisa N Diagnosisb Type of study % Female Mean age Country
Nielsen14 II 136 BD C-S N.K. N.K. Denmark
Malleson et al15 II, IVc 14 MDD TT N.K. N.K. UK
Bjørum45 II, IV 60 Depression TT with C-S 67 51 Denmark
Bjørum et al46 II, IV 68 Depression TT with C-S 75 47 Denmark
Naylor et al47 II, IV 62 BD TT with C-S 65 N.K. UK
Herzberg & Herzberg48 II 119 MDD C-S 41 32 Australia
Ramsey et al49 II, IV 83 BD, MDD TT with C-S 27 N.K. USA
Sengupta et al50 IV 131 BD, MDD TT with C-S 48 N.K. India
Strzyzewski et al50 II, IVc 46 BD, MDD TT 57 37 Poland
Frazer et al51 II, IV 194 BD, MDD C-S 51 46 USA
Thakar et al52 IV 140 BD, MDD C-S 57 40 Canada
Alexander et al53 IV 47 BD C-S 53 34 Lebanon
Banki et al54 II, IV 34 MDD C-S 100 42 Hungary
Linder et al55 II, IV 83 (rem) MDD TT + C-S 50 53 Sweden
Kirov et al56 II, IV 319 BD, MDD TT + C-S N.K. 36 Bulgaria
Widmer et al57 II, IV 53 BD, MDD TT + C-S 49 48 Switzerland
Widmer et al58 II, IV 101 BD, MDD C-S 53 46 Switzerland
Young et al59 II 225 BD, MDD C-S 61 37 Canada
Kamei et al60 II, IV 51 (rem) MDD TT + C-S 35 38 Japan
Walker et al61 III 71 Depression TT 100 NK UK
Levine et al62 II 29 BD, MDD C-S 59 56 USA
De Souza et al III 42 Depression TT 100 32 UK
Zieba et al64 II 35 MDD C-S 51 40 Poland
Imada et al65 II 101 BD, MDD C-S 43 45 Japan
Sharkey et al66 I 279 Depression C-S 100 ∼80 USA
Hornyak et al67 III 11 Depression TT 55 47 Germany
Bhudia et al31 III 273 Depression TT 23 64 USA
Daini et al68 II, IV 162 MDD C-S 24 32 Italy
Barragan-Rodrìguez et al69 II 110 Depression C-S 75 77 Mexico
Barragan-Rodrìguez et al70 III 23 Depression TT 52 68 Mexico
Iosifescu et al71 II 29 MDD TT 57 42 USA
Nechifor72 II 76 MDD TT ∼75 N.K. Romania
Jacka et al27 I 5708 Depression C-S 57 48 Norway
Rondanelli et al73 III 43 Depression TT 63 78 Italy
Bae & Kim74 I, II 105 Depression C-S 100 49 Rep. of Korea
Camardese et al75 II 123 MDD C-S 54 48 Italy
Huang et al76 I, II 210 MDD C-S 53 72 Taiwan
Jacka et al77 I 1023 MDD C-S 100 51 Australia
Cubala et al78 II 40 MDD C-S 58 32 Poland
Yary et al79 I 402 Depression C-S 43 33 Malaysia
Büttner et al80 II 30 MDD TT 43 46 Germany
Kim et al81 I 849 Depression C-S 100 15 Rep. of Korea
Miki et al82 I 2006 Depression C-S 11 42 Japan
Misztak et al83 II 179 BD C-S 61 45 Poland
Rajizadeh et al84 II 650 Depression C-S 70 34 Iran
Styczeń et al30 II 164 MDD C-S 75 N.K. Poland
Tarleton & Littenberg85 I 8894 Depression C-S 53 46 USA
Fard et al86 III 95 Depression TT 100 28 Iran
Gu et al87 II 329 MDD PROS + C-S 37 60 China
Martínez-Gonzalez et al88 I 15 836 MDD PROS 59 38 Spain
Rubio-López et al89 I 710 Depression C-S 52 8 Spain
Yary et al28 I 2320 Depression PROS + C-S 0 53 Finland
Bambling et al90 III 12 MDD TT 66 49 Australia
Mehdi et al91 II, III 12 MDD TT 75 47 USA
Miyake et al92 I 1745 Depression C-S 100 31 Japan
Rajizadeh et al32 III 60 Depression TT 73 32 Iran
Szkup et al93 II 198 Depression C-S 100 56 Poland
Tarleton et al94 III 112 Depression TT 62 53 USA
ADs, antidepressants; BD, bipolar disorder; C-S, cross-sectional; MDD, major depressive disorder; PROS, prospective; REM, remitted; TT, treatment trial.
a. This column indicates in which meta-analysis the study in the corresponding row was included:
I Dietary Mg2+ in relation to mood disorder prevalence and incidence; II Mg2+ in bodily fluids of patients and healthy control subjects or Mg2+ in relation to symptom severity; III Mg2+
supplements as an antidepressant; IV additional analyses ([1] differences in Mg2+ levels in bodily fluids between patients with mood v. other psychiatric disorders, [2] pre-post treatment
(with antidepressants and/or mood stabilisers) differences in Mg2+ levels in bodily fluids, and [3] Mg2+ ATPase in erythrocytes or platelets; see Results section).
b. We distinguish depression from MDD here. Depression refers to self-reported symptoms, MDD to the diagnosed syndrome.
c. This study reported on changes in Mg2+ levels over the course of treatment in a single patient sample only.
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(a) Dietary Mg2+ in relation to mood disorder prevalence and incidence
OR (95% CI) on unipolar depression/symptoms k n I2 Egger’s t
k n I2 Egger’s t
k n I2 Egger’s t
k n I2 Egger’s t
Cross-sectional data
Prospective data
12 21,927 95.2*** –2.8*
2 18,156 4.2* N.A.
1.00.50.0 1.5 2.0
High Mg2+ diet Low Mg2+ diet
(b) Mg2+ in bodily fluids
Hedge’s g (95% CI) on continuous differences
Hedge’s g (95% CI) on continuous differences
Hedge’s g (95% CI) on post-treatment differences
Overall 2.95**
By disorder/assessment
Major depressive disorder 
Depressive symptoms
Bipolar disorder
By treatment status1
Treated
Untreated
Overall
By disorder/assessment
Major depressive disorder 
Depressive symptoms
Bipolar disorder
By treatment status
Treated
Untreated
Not known / mixed
(c) Mg2+- symptom severity
N.A.
N.A.
–1.0 –0.5 0.0 0.5 1.0
–1.0 –0.5 0.0 0.5 1.0
Low in mood disorder High in mood disorder
Low in mood disorder High in mood disorder
(d) Mg2+ supplements as an antidepressant
Overall2
Control condition 
No control condition 
62 4,433 76.1**
23 1,574 67.5** –0.6
19 1,510 81.2** 5.2**
21 1,349 66.8** 0.9
17 1,164 74.9** 0.8
42 2,830 70.0** 3.5**
4 439 55.1 0.0
11 827 28.2 –0.07
7 378 31.0 –0.26
2 175 72.1
2 274 0.0
3 331 61.7 2.8
8 496 0.5 0.1
11 714 59.7** –1.7
8 538 30.9 –0.8
  3 131 8.0  0.9
–2.0 –1.0 0.0
*
** <
1.0 2.0
Favours Mg2+ Favours control/Dbaseline
**
**
**
**
*
Fig. 2 Results of themeta-analyses, heterogeneity, and publication bias assessment.A: dietary Mg2+ intakewas associatedwith prevalence of
depression but not with incidence of depression. B: patients with mood disorders on average had higher levels of Mg2+, and this effect was
driven by treatment status.C: Non-significant associations between the amount of Mg2+ in bodily fluids andmood disorder severity. E: Change in
mood disorder symptoms over the course of treatment with Mg2+ supplements. 1: The effect-size estimate for differences in Mg2+ between
patients with a mood disorder and healthy control subjects was significantly different for treated v. non-treated patients. 2: The effect-size
estimate for changes in mood disorder symptoms was statistically significantly different at P < 0.01 when comparing studies that applied a
(placebo) control v. those studies that compared pre- v. post-treatment scores.
N.A., not applicable (because <3 estimates were available).
Note. Results provided in parts B and C were not driven by the type of bodily fluid in which Mg2+ was measured.
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Additional analyses
Three meta-analyses were performed which were not a priori
defined but driven by the data that we encountered.
The first analysis explored between-group differences in Mg2+
levels in bodily fluids between patients with mood disorders
versus other psychiatric disorders. Pooling 11 associations (n =
508) showed little evidence for the existence of such an association
(g =−0.07, 95% CI =−0.47–0.33; P = 0.47).
The second analysis quantified pre–post treatment (with antide-
pressants and/or mood stabilisers) changes in Mg2+ levels in bodily
fluids. A total of 17 effect-size estimates on this association (n = 223)
showed no evidence for the existence of such changes (g =−0.09,
95% CI =−0.27–0.10; P = 0.36).
Finally, we pooled 13 effect-size estimates from three studies
(n = 545) on between-group differences in Mg2+-ATPase (the
enzyme that mediates the transport of Mg2+ across the cell mem-
brane).1,95 We found higher Mg2+-ATPase activity in patients with
depression relative to controls (g = 0.69, 95%CI = 0.42–0.93;P < 0.001).
Discussion
We quantitatively pooled the available human data on the involve-
ment of Mg2+ in the pathophysiology of mood disorders. A
summary and discussion of our results is presented below, arranged
by the type of association investigated.
Dietary Mg2+ and the prevalence and incidence of mood
disorders
We found that adherence to a diet high inMg2+ was negatively asso-
ciated with prevalence of depression in cross-sectional studies. Note
that all studies investigated associations with major depression or
depressive symptoms, but not bipolar disorder. This suggests that
dietary Mg2+ intake may play a part in the pathology of depression.
However, the cross-sectional design of these studies precludes any
causal association or conclusions being made regarding the direc-
tion of the effect.
Furthermore, the sources of heterogeneity that we observed
weaken the rationale for this association. Considerable between-
study heterogeneity in outcome was observed, and sample size
was the only variable which moderated this heterogeneity; studies
that included fewer subjects tended to report a stronger association
between dietary Mg2+ and prevalence of depression. We found
evidence of publication bias when we used formal tests to assess
this bias, which is in keeping with this small-study effect.96
The belief in an association between dietary Mg2+ intake and
depression may be further weakened by the lack of a significant
association between dietary Mg2+ intake and the incidence of
depression in longitudinal studies (epidemiological cohorts).
However, the number of longitudinal studies was limited, and not
only was the point estimate for the effect from these studies
rather similar to the pooled estimate for cross-sectional studies
(ORs of 0.71 and 0.66, respectively), but their confidence intervals
were also widely overlapping. This, together with the observation
of between-study heterogeneity, leaves it open to debate on
whether the effect is sufficiently strong as to be clinically relevant.
A lack of statistical evidence for the existence of an association
in longitudinal studies could suggest reverse causation, i.e. in the
depressed state, the likelihood of adhering to a diet low in Mg2+
may be increased. This is in line with evidence which demonstrates
that mood disorders set the stage for a low-quality diet, which by
extension is low in Mg2+.5,97,98 Additionally, the evidence indicating
that the quality of the diet may cause – de novo – depression is sug-
gestive, but limited and not fully consistent.99 On the other hand,
the results from two recent randomised trials 100,101 suggest that
dietary advice may alleviate depressive symptoms in patients who
already are depressed, although it may be questioned whether this
effect is solely due to a change of diet or to other factors such as
selective expectancies.102
Mg2+ levels in bodily fluids as a function of mood
disorder status
Against expectations, we found higherMg2+ levels in bodily fluids in
patients with a mood disorder relative to healthy control subjects.
This effect was moderated by treatment status; Mg2+ levels were
high in patients treated with antidepressants and/or mood stabili-
sers and were not so in untreated patients. Perhaps this observation
reflects the hypothesis that an increase in Mg2+ may underlie the
clinical efficacy of (fast-acting) antidepressants.17 However, alterna-
tive explanations may account for this finding. Dehydration for
instance is one; antidepressants and mood stabilisers decrease
renal water reabsorption,103 which can lead to dehydration, a
common side-effect of antidepressants.104 This may result in artifi-
cially high concentrations of trace elements. Other potential con-
founding factors are presented below.
Notwithstanding the lack of a clear and single explanation for
the higher levels of Mg2+ in treated patients, the similar Mg2+
Table 2 Meta-regression coefficients and standard error on the relation between study characteristics and effect-size estimates, separately for the
different indicators that are in use to operationalise the hypothesis of Mg2+ involvement in mood disorders
Dietary Mg2+ a
k = 12
n = 21 927
Fluid Mg2+ b
k = 62
n = 4433
Fluid Mg2+ c
k = 11
n = 827
Mg2+ treatment
k = 11
n = 714
Year −0.007 (0.055) 0.008 (0.009) 0.005 (0.008) 0.015 (0.039)
N 0.0001 (0.001)* −0.005 (0.001)** 0.001 (0.001) 0.002 (0.003)
Age of the sample −0.009 (0.008) −0.001 (0.010) 0.001 (0.006) 0.004 (0.014)
% Female −0.003 (0.007) −0.002 (0.004) −0.002 (0.003) 0.016 (0.013)
Methodological quality −0.046 (0.165) 0.001 (0.061) −0.014 (0.073) −0.377 (0.695)
Treatment weeks N.A. N.A. N.A. −0.082 (0.073)
N.A., not applicable.
In order to aid with interpretation, we include a synopsis. Sample size was positively associated with the effect-size estimates in dietary studies; this indicates that smaller samples on
average yielded stronger associations between dietary Mg2+ and depression prevalence (the strength of this association in terms of Spearman’s rho (ρ) was 0.61). Sample size was negatively
associated with the effect-size estimates in studies investigating differences in Mg2+ in bodily fluids between patients and healthy control subjects. This means that smaller samples on
average yielded larger differences (the strength of this association was ρ =−0.42).
a. Results are presented for cross-sectional data only. There were only two prospective studies available and hence separate meta-regression analyses were not possible. Results from the
analyses were no different when the prospective studies were pooled with the cross-sectional.
b. Mean differences in bodily fluid Mg2+ levels between patients with a mood disorder and healthy control subjects.
c. Continuous differences in bodily fluid Mg2+ levels as a function of mood disorder symptom severity.
* P < 0.05; **P < 0.01.
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levels in untreated patients and healthy control subjects suggest little
involvement of (peripheral) Mg2+ in the pathophysiology of mood
disorders.
Changes in mood following treatment with Mg2+
supplements
In line with expectations, we found that treatment with Mg2+ sup-
plements was associated with a decline in depressive symptoms.
This effect was moderated by study type. The supposed therapeutic
efficacy of Mg2+ supplements onmood was only observed in uncon-
trolled studies; in controlled studies, they did not have a superior
effect compared with placebo. Therefore, the effect of Mg2+ supple-
ments on mood may merely represent a placebo effect. This finding
does not corroborate the hypothesis that Mg2+ affects the patho-
physiology of mood disorders.17,19
Additional analyses
We performed three additional meta-analyses that were driven by
the data that we encountered. The first of these showed no group
differences in Mg2+ levels in bodily fluids in patients with mood dis-
orders versus patients with other psychiatric disorders. The second
provided no evidence for differences in Mg2+ levels pre- and post-
treatment with an antidepressant and/or mood stabiliser. Finally,
Mg2+–ATPase, the enzyme that mediates the transport of Mg2+
across the cell membrane,1,94 showed higher activity in patients rela-
tive to healthy controls. The effect size of this association was large,
but it was derived from only three studies.
We will not discuss these findings further given the limited
number of studies and their exploratory nature.
Comparison with previous meta-analyses
Our findings stand out from two previous meta-analyses in that our
analysis included amore comprehensive collection of articles, which
were pooled by type of association.
Cheungpasitporn et al 34 pooled data from three studies on
blood Mg2+ levels and two studies on dietary Mg2+ intake and con-
cluded that hypomagnesaemia was related to depression. Our
results are not in line with their conclusion. This discrepancy may
be due to the heterogeneous nature of the studies pooled by
Cheungpasitporn et al.34 Furthermore, we do not speak in terms
of hypomagnesemia, because the data do not allow that. As men-
tioned previously, hypomagnesemia refers to <0.7 mmol Mg2+l/L
blood,9 and the included studies on Mg2+ in blood do not report
on this; they report on continuous values instead. Additionally,
information on hypomagnesemia cannot be estimated from diet.
Hence, Cheungpasitporn et al34 probably refer to low levels of
Mg2+ when using the term hypomagnesemia.
Our findings from cross-sectional dietary data are similar to
those reported by Li et al.35 What we add is the crucial separation
between cross-sectional and prospective data. As we have shown,
results from these two types of data are clearly distinct, with evi-
dence for an association between dietary Mg2+ and depression in
cross-sectional but not prospective studies.
Limitations
Our results should be interpreted in light of the following limita-
tions, many of which relate to measurement error and confounding.
In the case of confounding, it is likely that in our meta-analyses we
overestimated the strength of associations. By contrast, with regards
to measurement error, it is more likely that the effect-size estimates
we reported on the associations of interest are an underestimation of
the true effect. In extreme cases, measurement error may even have
led to a lack of construct validity and an inability to assess certain
associations.
Most studies that we reviewed were observational in nature,
except for some treatment studies; therefore, our results may have
been affected by residual confounding. For example, Mg2+ is
derived from diet,3,4 and diet is influenced by income-related dis-
parities97,105 and many other such variables. Each of these variables
may have effects on the outcome that are difficult to distinguish
from the effects of Mg2+ intake. Another limitation related to the
dietary data was that only one single assessment of dietary practices
was applied in each of the included studies. One single assessment
may not be enough to capture dietary habits and the dietary
changes that may have occurred. Finally, the investigators of the
included studies calculated the Mg2+ in nutrients in order to
reach an overall Mg2+ estimate and in doing so ignored a relevant
source of dietary Mg2+; tap and bottled water.106
The Mg2+ measurements in bodily fluids, as they were per-
formed in the included studies, were also limited. First, they were
all taken in peripheral tissues, while the pathophysiology of the
mood disorders is believed to reside in the brain. Although positive
correlations have been reported between central and peripheral
Mg2+ parameters, there clearly is not a one-to-one relationship
between them.107,108 Furthermore, the included studies extracted
isolated Mg2+ parameters (e.g. Mg2+ levels from blood serum).
This is a limitation because Mg2+ levels and receptor systems inter-
act and as such probably define biological outcome; single measure-
ments may simply not be rigorous or elaborate enough, and as such
the findings in this field of study may lack construct validity.
A general limitation is that the mood disorders are highly het-
erogeneous, whereas in the included studies they were not concep-
tualised as such. Perhaps, subtypes of mood disorders exist in which
Mg2+ plays an important part, and this is overlooked when broad
disorders are included and presented as if they were the same
outcome variable. Finally, the populations under study were
largely Caucasian, sample sizes were generally quite small and
follow-up periods were relatively short.
Future work
Future studies could assess multiple dietary and Mg2+ parameters at
multiple time points and define their potential interacting effect on
mood disorder incidence, course and subtype while accounting for
time-related changes in other variables such as body mass index.
Such an investigation would aid construct validity by reducing the
potential influence of measurement error. Moreover, the study of
Mg2+ and the mood disorders could use a certain amount of
control, for instance in the form of randomly assigned long-term
dietary interventions. This may reduce the potential influence of
residual confounding on outcome. Ideally, such studies would be
based on validated animal models and specific knowledge of the
potential underlying mechanisms.
Conclusion
The question of interest here was whether Mg2+ is involved in the
pathophysiology of the mood disorders. This association seems
plausible, yet the results of our analyses by and large do not
provide compelling evidence for the involvement of Mg2+ in
mood disorders. Although this conclusion is based on the largest
and most comprehensive body of human data to date, there are
methodological and practical limitations that may have hindered
valid assessment of the associations of interest. Future studies
should aim to reduce confounding and measurement error in
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order to increase knowledge on the potential role of Mg2+ in the
pathophysiology of the mood disorders.
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Appendices
Appendix 1 PRISMA checklist
Section/topic # Checklist item
Reported on page
#
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
Abstract
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.
2
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known. 3
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).
4
Methods
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g. Web address), and, if available,
provide registration information including registration number.
4
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. years
considered, language, publication status) used as criteria for eligibility, giving rationale.
4
Information sources 7 Describe all information sources (e.g. databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
4
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.
4
Study selection 9 State the process for selecting studies (i.e. screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
4,5
Data collection process 10 Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators.
5 and appendix
Data items 11 List and define all variables for which data were sought (e.g. PICOS, funding sources) and any assumptions
and simplifications made.
5 and appendix
Risk of bias in individual
studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether
this was done at the study or outcome level), and how this information is to be used in any data
synthesis.
5 and appendix
Summary measures 13 State the principal summary measures (e.g. risk ratio, difference in means). 5
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g. I2) for each meta-analysis.
4 and 5
Risk of bias across
studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias,
selective reporting within studies).
4 and appendix
Additional analyses 16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-regression), if done,
indicating which were pre-specified.
5
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
5, 6
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g. study size, PICOS, follow-up
period) and provide the citations.
Table 1 and
appendix
Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 4 and appendix
(Continued )
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Appendix 2 MOOSE checklist
(Continued )
Section/topic # Checklist item Reported on page
#
Results of individual
studies
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
6,7
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 6,7
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item 15). 4 and appendix
Additional analysis 23 Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-regression; see
Item 16).
6
Discussion
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main outcome; consider their
relevance to key groups (e.g. healthcare providers, users, and policy makers).
7
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias), and at review-level (e.g. incomplete
retrieval of identified research, reporting bias).
7, 8
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future
research.
7,8
Funding
Funding 27 Describe sources of funding for the systematic review and other support (e.g. supply of data); role of
funders for the systematic review.
1
Criteria Brief description of how the criteria were handled in the meta-analysis
Reporting of background should include
√ Problem definition There is a considerable amount of human data on the topic. Some studies
evaluated whether the prevalence (in cross-sectional studies) or the
incidence of depression (in longitudinal cohorts) differs as a function of
dietary Mg2 intake. Others have investigated Mg2+ in bodily fluids as a
function of mood disorder status. Some experiments also have investigated
whether Mg2+ supplementation can serve as an antidepressant. However,
the findings from these studies appear to be inconclusive and the 2 meta-
analyses on the topic to date do not provide a high level of evidence either.
√ Hypothesis statement Mg2+ deficiency also poses a risk to mental health, in particular to a (pathological)
low mood
√ Description of study outcomes (I) the prevalence and incidence of depression (II) Mg2+ levels by mood disorder
status/severity, and (III) improvement in mood
√ Type of exposure or intervention used (I) dietary Mg2+ intake, (II) mood disorder status/severity, and (III) Mg2+
supplements
√ Type of study designs used Case-control studies, cross-sectional studies, prospective studies, treatment
trials, randomised controlled trials
√ Study population No restriction applied
Reporting of search strategy should include
√ Qualifications of searchers The credentials of the investigators are indicated at the title page
√ Search strategy, including time period included in the synthesis
and keywords
Systematic searches in PubMed, Web of Science (WoS) and Embase (from their
commencement to 22 December 2017
√ Databases and registries searched PubMed, WoS, and Embase
√ Search software used, name and version, including special
features
WoS 2017
√ Use of hand searching Bibliographies of the retrieved papers (only the included studies) were hand
searched for additional references and backward searches were performed
regarding the two first papers on the topic
√ List of citations located and those excluded, including
justifications
Details of the literature search process are outlined in the PRISMA flow chart
including reasons for exclusions
√ Method of addressing articles published in languages other than
English
Papers had to be written in English, French, German, Spanish or Dutch in order to
be included. All articles however were written in English
√ Method of handling abstracts and unpublished studies We contacted a number of authors for full report of relevant unpublished studies
in case we found an abstract and no paper
√ Description of any contact with authors We contacted authors of relevant articles for necessary information in case that
was not provided in the article
Reporting of methods should include
√ Description of relevance or appropriateness of studies assembled
for assessing the hypothesis to be tested
Detailed inclusion and exclusion criteria are described in the paper
√ Rationale for the selection and coding of data A data extraction sheet was developed (available on request). Data extracted
were related to bibliographic details of included study, method of
identification of the study, Characteristics of cases/ controls, outcomes and
quality assessment
(Continued )
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Appendix 3 Study protocol
Working title of the project
Magnesium and disorders of mood: a systematic review with meta-
analyses
Review question(s)
1. Does mood disorder prevalence or incidence vary by dietaryMg2
+ intake.
2. DoMg2+ levels in bodily fluids vary by mood disorder status and
severity.
3. Does Mg2+ supplementation have an effect on mood.
Searches
We conducted comprehensive searches in three major databases:
PubMed, Web of Science, and Embase through December 2017.
We used the following terms: (Magnesium OR Mg*) AND
(depression OR depress* OR affect* OR mood OR mania OR
bipolar).
The reference-lists of identified articles were scrutinised, as were
the references that were made to the 2 seminal papers on the topic
(Nielsen, 1964 and Malleson, Frizel, and Marks, 1968) to which, at
the date of our latest search, 65 and 5 references were made
respectively).
Nielsen J. Serum and erythrocyte magnesium in patients with
manic states during lithium treatment. Acta Psychiatr Scand 1964;
40(2): 190–6.
Malleson A, Frizel D, Marks V. Ionized and total plasma
calcium and magnesium before and after modified ECT. Br J
Psychiatry 1968; 114(510); 631–33.
Types of study to be included
1. Cross-sectional or prospective studies or randomised controlled
trials on the relation between dietary Mg2+ intake and the preva-
lence or incidence of a mood disorder (unipolar or bipolar
depression of any kind).
2. Cross-sectional or prospective studies or randomised controlled
trials on Mg2+ levels in bodily fluids as a function of mood dis-
order status and severity.
3. Open- or blinded trials (random and non-random, including
one-group pre-post designs) reporting on the effects of Mg2+
supplementation on any type of mood outcome (e.g. self- and
clinician rated questionnaires, diagnosis).
Condition or domain being studied
Psychiatry; mood disorders (unipolar or bipolar depression of any
kind).
Participants/population
No restrictions
Intervention(s), exposure(s)
1. Dietary Mg2+ intake as measured by a food frequency question-
naire, recall, or diary.
2. Mood disorder status versus healthy control status including
gradations in this defined by severity.
3. Mg2+ supplementation on any type and any dose.
(Continued )
Criteria Brief description of how the criteria were handled in the meta-analysis
√ Assessment of confounding We conducted sensitivity analyses where possible and relevant by requesting
results by type of diagnosis, type of blood compartment in which Mg was
measured, and type of study.
√ Assessment of study quality, including blinding of quality
assessors; stratification or regression on possible predictors of
study results
The methodological quality of cross-sectional- and case-control studies was
assessed using the Newcastle–Ottawa scale and that of prospective studies
using the method proposed by Lievense et al. The methodological quality of
treatment trials was assessed using the method of evaluation of
(randomised) trials provided by the US Department of Health and Human
services. Study quality was related to outcome as a continuous moderator.
√ Assessment of heterogeneity We used the I2 and Q values to assess heterogeneity
√ Description of statistical methods in sufficient detail to be
replicated
We mentioned type of analysis we used (random-effects meta-analysis and
subgroup meta-analysis) and type of software we used (STATA)
√ Provision of appropriate tables and graphics We included a PRISMA flow chart to show the method of studies identification,
Table1 shows characteristics of included studies, Table 2 provides the results
from moderator analyses. Figure 2 provides the main results, and those by
subgroup.
Reporting of results should include
√ Graph summarising individual study estimates and overall
estimate
Not provided. The number of studies was so large that a forest plot would not be
interpretable
√ Table giving descriptive information for each study included Table 1 and Supplementary Table 10
√ Results of sensitivity testing Figure 2
√ Indication of statistical uncertainty of findings 95% CI intervals were presented around point estimates for all analyses together
with I2 and Q values
Reporting of discussion should include
√ Quantitative assessment of bias All analyses are discussed in light of bias and limitations.
√ Justification for exclusion This is presented in detail in the flow-chart and the result section
√ Assessment of quality of included studies Quality of the studies was related to outcome in all analyses
Reporting of conclusions should include
√ Consideration of alternative explanations for observed results We emphasise alternative explanations for our results (reverse causation,
confounders and measurement error)
√ Generalisation of the conclusions We reported the fact that almost all of the studies were on participants of
Caucasian descent
√ Guidelines for future research We suggest future work with lower potential for confounding and measurement
error
√ Disclosure of funding source No funding was required for conducting this review
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Comparator(s)/ control
1. High versus low Dietary Mg2+ intake of any kind (e.g. continu-
ous, highest quartile versus lowest quartile).
2. Healthy control condition.
3. Placebo (blinded and non-blinded), active control condition
(blinded and non-blinded), pre-post measurement in a single
group.
Outcome(s)
Primary outcomes (ABS).
• Question 1. Prevalence and incidence of mood disorders.
• Question 2. Blood levels (in any blood component/bodily fluid)
of Mg2+.
• Question 3. Changes in mood of any type.
Secondary outcomes. Not applicable
Data extraction
Two of the authors (Danny Phelan and Marc Molendijk) independ-
ently screened titles and abstracts of potentially eligible articles.
When indicated, this was followed by a review of the full texts of
potentially candidate papers. Any type of disagreement with
regard to inclusion was resolved by consensus after discussion
with a third author.
Risk of bias (quality) assessment
The Newcastle-Ottawa Scale (NOS) cohort version (Wells et al,
2016) was used to assess the methodological quality of the included
cross-sectional studies on the association between dietary Mg2+
intake and the prevalence of mood disorders.
The prospective cohort studies on the relation between dietary
Mg2+ intake and the incidence of mood disorders were assessed
regarding their methodological quality by using the method pro-
posed by Lievense et al (2002).
The NOS case-control version (Wells et al, 2016) was used to
assess the methodological quality of the included cross-sectional
studies on the association between abnormalities in Mg2+ levels in
blood components/bodily fluids as a function of mood disorder status.
Methodological quality of treatment trials on changes in mood
over the course of Mg2+ supplementation was assessed by means of
the method of evaluation of (randomised) trials provided by the US
Department of Health and Human services (2016).
Lievense AM, Bierma‐Zeinstra SMA, Verhagen AP, Van Baar
ME, Verhaar JAN, Koes BW. Influence of obesity on the develop-
ment of osteoarthritis of the hip: a systematic review. Rheumatol,
2000; 41(10): 1155–62.
The US Department of Health and Human services, National
Heart, Lung and Blood Institute http://www.nhlbi.nih.gov/health-
pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/rct.
Wells, G. A., Shea, B., O’Connell, D., Peterson, J., Welch, V.,
Losos, M., & Tugwell, P. (2013). The Newcastle-Ottawa Scale
(NOS) for assessing the quality of nonrandomized studies in
meta-analyses. 2009. Epub Available from: http://www.ohri.ca.
Strategy for data synthesis
Quantitative synthesis will be performed by means of random-
effects meta-analyses performed in STATA version 13 (2013).
StataCorp LP. (2013). Stata Statistical Software: Release 13-stat-
istical software. College Station, TX.
Analysis of subgroups or subsets
To examine the potential source of heterogeneity across studies, the
following sensitivity analyses (per question) were conducted:
• Question 1. Analyses by study type (cross-sectional / prospective
studies / randomised controlled trials)
• Question 2. Analyses by disorder (major depressive disorder /
depressive symptoms / bipolar disorder / mania), treatment
status (antidepressants / electroconvulsive therapy / untreated
/ not known), blood component / bodily fluid (plasma /
serum / urine / cerebrospinal fluid).
• Question 3. Analyses by disorder (major depressive disorder /
depressive symptoms / bipolar disorder / mania), control condi-
tion (yes / no).
Sources of heterogeneity were also investigated by means of
meta-regression analyses with sample size, average age of the
sample, female percentage of the sample and methodological
quality of the study as predictor. For the third question we
also regressed number of weeks of treatment and Mg2+ on
outcome.
Organisational affiliation of the review
None
Anticipated or actual start date
July 2016
Anticipated completion date
December 2017
Funding sources/sponsors
The review and meta-analyses were supported by a Leiden
University research appointment (Marc Molendijk).
Language
English
Country
The Netherlands
Subject index terms
Depression, mood, bipolar disorder, mania, trace-elements, magne-
sium, Mg2+, diet, review, meta-analysis
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